Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14

January 22, 2019 updated by: Orpha Labs
Study of ORL-1G in Patients With Glycogen Storage Disease Type 14

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

5

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 18 years (ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of Glycogen Storage Disease Type 14.
  • Less than 18 years old.

Exclusion Criteria:

  • Diagnosis of any other disease that is not a manifestation of Glycogen Storage Disease Type 14.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Treatment with ORL-1G - D-galactose
Drug: ORL-1G - D-galactose
Oral ORL-1G - D-galactose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Improvement in liver function.
Time Frame: 3 months after treatment starts
Statistically significant decrease in plasma liver enzyme levels
3 months after treatment starts

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Improvement in serum transferrin glycosylation pattern.
Time Frame: 30 days after treatment starts
Decreased serum level of hypoglycosylated transferrin.
30 days after treatment starts

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Orpha Labs

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 31, 2017

Primary Completion (ANTICIPATED)

October 31, 2019

Study Completion (ANTICIPATED)

October 31, 2019

Study Registration Dates

First Submitted

January 13, 2018

First Submitted That Met QC Criteria

January 13, 2018

First Posted (ACTUAL)

January 19, 2018

Study Record Updates

Last Update Posted (ACTUAL)

January 25, 2019

Last Update Submitted That Met QC Criteria

January 22, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GALA-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glycogen Storage Disease, Type 14

Clinical Trials on ORL-1G - D-galactose

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe